Diagnostics, Volume 15, Issue 2
2025 January-2 - 118 articles
Cover Story: This study evaluated the clinical utility of the PrecivityAD2™ blood test (C2N Diagnostics, St. Louis, MO) that reveals the likelihood of brain amyloid plaques. After receiving the blood biomarker test results, clinicians completed surveys on management strategies for each patient. Among 203 patients presenting with symptoms of Alzheimer’s disease (AD) across 12 memory specialists, the composite primary endpoint—defined as a change in AD diagnostic certainty, drug therapy, or additional brain amyloid evaluation pre- and post-BBM testing—was 75% (p < 0.0001 versus the pre-specified threshold of 20% clinically meaningful change). This blood biomarker test can help memory specialists guide patients to anti-AD therapies as well as rule out AD to allow for other diagnostic considerations. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.